Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4205 - MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines

Date

10 Oct 2016

Session

Poster display

Presenters

Hazel Lote

Citation

Annals of Oncology (2016) 27 (6): 545-551. 10.1093/annonc/mdw393

Authors

H. Lote1, D. Zito1, R. Burke2, E. Smyth3, C. Braconi4, D. Cunningham5, N. Valeri6

Author affiliations

  • 1 Laboratory Of Gastrointestinal Cancer Biology And Genomics, Division Of Molecular Pathology, The Institute of Cancer Research ICR, SM2 5NG - Sutton/GB
  • 2 Cancer Therapeutics, Institute of Cancer Research ICR, SM2 5NG - London/GB
  • 3 Department Of Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton/GB
  • 4 Signal Transduction And Molecular Pharmacology, The Institute of Cancer Research ICR, SM2 5NG - Sutton/GB
  • 5 Department Of Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 6 Laboratory Of Gastrointestinal Cancer Biology And Genomics, Division Of Molecular Pathology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5NG - Sutton/GB
More

Resources

Abstract 4205

Background

MicroRNAs (miRs) may be involved in primary resistance to HER2 inhibitors and represent a clinically useful biomarker for gastro-oesophageal cancer (GOC) patients with HER2 amplified disease. Identification of miRs responsible for resistance to HER2 inhibitors may allow us to develop a novel, reproducible, non-invasive and cost-effective tool for GOC patient stratification. Defining predictive biomarkers of resistance to HER2 inhibitors would enable patient selection, minimise chances of severe toxicity in those less likely to respond, and may define novel strategies to restore drug sensitivity.

Methods

A high-throughput large-scale RNA interference screen in the HER2-amplified GOC cell line NCI-N87 and the HER2-non-amplified cell line FLO-1 was performed in order to discover novel miRs involved in sensitivity and resistance to trastuzumab. Cells were transfected using a library of 1015 miR mimics, control miRs and siRNAs, and siPLK1 positive control. They were treated 48 hours later with cisplatin + 5FU + trastuzumab based on IC50 data previously obtained. Cell viability was analysed after 72 hrs of continuous drug treatment by fluorescence-based assay (Cell Titer Blue® and EnVision™). Data from 3 biological replicates was analysed and shortlisting of significant hits was based on the concordance among data from different replicates. miRs were considered significant if they caused >40% decrease in cell viability with a t-test p value of

Results

Thirty-two miRs caused >40% decrease in cell viability and were associated with a p value of 40% decrease in cell viability and were associated with a p value of

Conclusions

We identified a panel of miRs associated with GOC resistance to HER2 inhibitors in combination with chemotherapy. Inhibition of these miRs significantly affects GOC cell viability and and restores sensitivity to HER2 inhibitors plus chemotherapy. These miRs require validation with Exiqon miR inhibitors and Nanostring analysis. Translational studies will be conducted in the ST03 HER2 substudy (EUDRACT 2006-000811-12).

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Cancer Research UK

Disclosure

D. Cunningham: Institution has received research funding from AstraZeneca, Amgen, Celgene, Merck Serono, Sanofi, Merrimack, and Medimmune. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings